Curewiki
Bridging the Gap between Patients and Breakthrough Treatments

Clinical trials are steadily shifting from traditionally rigid, study-centric models to more patient-centric approaches that prioritise engagement and experience. While the pharmaceutical industry and contract research organisations are making significant strides in this direction, Curewiki is helping them by embedding patient-centricity at the very foundation of their trial participation. The mission is simple: Empowering patients with choice and a wealth of options drives clinical research forward and ultimately improves trial outcomes.

How is it achieved?

Ease of use is the name of the game. Curewiki’s platform provides a user-friendly environment for patients to register, build a dynamic profile and apply for trials. Individuals take control of their participation rather than being directed by hospitals and researchers towards specific studies, making the whole clinical trial recruitment process more accessible while ensuring patient voices are heard.

Why is this change so important?

Approximately 60 percent of patients are willing to participate in clinical trials if provided with necessary decision-making information. From a patient’s perspective, the current recruitment process can be overwhelming. Doctors, a major player in clinical trial recruitment, often get to highlight only a select few studies due lack of communication channels on their end, and this leads to a mismatch between patient needs and available trials. For those eager to participate, navigating through online platforms can be tedious. The presence of misinformation and convoluted medical terminology mostly in English creates a language barrier and leads to misconceptions regarding study eligibility, further complicating the process.

Curewiki emerges as a solution to this by prioritising patient needs and preferences. Its innovative process starts with the participant’s willingness. By analyzing user profiles (health status, geography, etc.), it matches patients with the most suitable studies. This dynamic matching ensures patients are paired with the most appropriate trials, increasing the likelihood of successful recruitment and retention. Augmenting the decentralised trial model is Curewiki’s agnostic approach that shows and proposes all clinical studies recognised by the official drug administrations, reducing barriers to participation and making the process more flexible and accessible and enhancing the overall patient experience.

For instance, individuals with cardiac issues might find over 100 potential studies. Engaging with Curewiki’s chatbot, they can quickly answer simple dynamic questions (based on trial criterias) and get a tailored list of studies with relevant information where they can participate. This simplifies decision-making process, ensuring they are matched to the best possible trials.

Not only patients, but this approach also benefits researchers and clinical trial managers. It helps reduce screening time and costs by pre-matching willing patients to relevant clinical trials based on inclusion or exclusion criteria, leading to higher enrolment rates and lower patient dropout risks.

“As the saying goes, it takes two to tango,” states Jean-Sébastien Gosuin, founder and CEO. “By streamlining the recruitment process, we ensure better patient engagement while making trials more efficient, reducing no-shows and facilitating smoother studies with a better chance of successful outcomes.”

Researchers can join the platform through a freemium model, add details about their trials and activate or deactivate specific study criteria to meet their screening needs. Once set up, the platform can anonymously identify potential candidates based on basic inclusion and exclusion criteria. Researchers receive details of shortlisted candidates only when there is a mutual match—when patients give consent, express interest and meet the trial requirements. If using the paid version, they can also choose specific unfinished patient profiles suitable for their study and encourage them to complete the application.

The success of the platform can be seen in the substantial market share it has captured in Europe. The platform currently hosts all trials in Belgium, the Netherlands, France and Germany, representing an impressive 10,000 out of the 25,000 trials currently recruiting in Europe. By the end of the third quarter, it aims to expand its reach to the UK, Spain and Italy, covering more than 80 percent of all European trials.

It’s evident that the potential of this platform is immense. By facilitating a more efficient and patient-centric approach to clinical trial recruitment, Curewiki is poised to accelerate the development of life-saving treatments making it one of the top 10 clinical trial management companies in 2024.